NALIRIFOX (iposomal irinotecan + 5-fluorouracil/feucovorin + oxaliplatin) versus FOLFOX [5-fluorouracil/leucovorin + oxaliplatin] as first-line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC): Real-world comparative overall survival Meeting Abstract
| Authors: | O'Reilly, E.; Li, J.; DerSarkissian, M.; Chang, R.; Cheng, M.; Yu, L.; Rane, D.; Zhang, L.; Xiao, Z.; Benzaghou, F.; Duh, M.; Chen, H. |
| Abstract Title: | NALIRIFOX (iposomal irinotecan + 5-fluorouracil/feucovorin + oxaliplatin) versus FOLFOX [5-fluorouracil/leucovorin + oxaliplatin] as first-line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC): Real-world comparative overall survival |
| Meeting Title: | 25th World Congress on Gastrointestinal Cancer (ESMO 2023) |
| Keywords: | oncology |
| Journal Title: | Annals of Oncology |
| Volume: | 34 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2023 Jun 28-Jul 1 |
| Meeting Location: | Barcelona, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2023-06-01 |
| Start Page: | S83 |
| Language: | English |
| ACCESSION: | WOS:001037960400191 |
| DOI: | 10.1016/j.annonc.2023.04.246 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: P-190 -- Source: Wos |
